Associated Banc Corp Cuts Position in Roche Holding AG (OTCMKTS:RHHBY)

Associated Banc Corp trimmed its position in shares of Roche Holding AG (OTCMKTS:RHHBYGet Rating) by 3.0% during the fourth quarter, Holdings Channel reports. The institutional investor owned 49,524 shares of the company’s stock after selling 1,540 shares during the quarter. Associated Banc Corp’s holdings in Roche were worth $2,576,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in RHHBY. First Horizon Advisors Inc. increased its stake in shares of Roche by 76.4% during the fourth quarter. First Horizon Advisors Inc. now owns 709 shares of the company’s stock worth $35,000 after buying an additional 307 shares during the period. Elmwood Wealth Management Inc. purchased a new position in Roche in the fourth quarter valued at approximately $128,000. Roanoke Asset Management Corp NY purchased a new position in Roche in the fourth quarter valued at approximately $207,000. Toroso Investments LLC purchased a new position in Roche in the third quarter valued at approximately $232,000. Finally, Dearborn Partners LLC increased its stake in Roche by 7.6% in the fourth quarter. Dearborn Partners LLC now owns 5,541 shares of the company’s stock valued at $288,000 after purchasing an additional 392 shares during the last quarter. Hedge funds and other institutional investors own 0.21% of the company’s stock.

Shares of OTCMKTS RHHBY traded up $0.21 during mid-day trading on Friday, hitting $39.75. 3,613,003 shares of the company were exchanged, compared to its average volume of 2,015,425. The company has a debt-to-equity ratio of 0.57, a current ratio of 0.93 and a quick ratio of 0.73. The stock has a 50 day simple moving average of $48.19 and a 200-day simple moving average of $48.83. Roche Holding AG has a 1-year low of $39.32 and a 1-year high of $53.86.

The business also recently declared a dividend, which was paid on Monday, March 28th. Investors of record on Friday, March 18th were issued a dividend of $0.7922 per share. This represents a dividend yield of 1.68%. The ex-dividend date of this dividend was Thursday, March 17th.

Several equities analysts have commented on RHHBY shares. Jefferies Financial Group lowered shares of Roche from a “buy” rating to a “hold” rating in a research note on Friday. Stifel Nicolaus started coverage on shares of Roche in a research note on Monday, February 28th. They issued a “buy” rating on the stock. JPMorgan Chase & Co. dropped their price target on shares of Roche from CHF 390 to CHF 370 and set a “neutral” rating on the stock in a research note on Friday, March 11th. Zacks Investment Research upgraded shares of Roche from a “sell” rating to a “hold” rating and set a $52.00 target price on the stock in a research report on Thursday, April 21st. Finally, Morgan Stanley lowered their target price on shares of Roche from CHF 395 to CHF 370 and set an “equal weight” rating on the stock in a research report on Thursday. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $310.50.

Roche Profile (Get Rating)

Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation.

See Also

Want to see what other hedge funds are holding RHHBY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roche Holding AG (OTCMKTS:RHHBYGet Rating).

Institutional Ownership by Quarter for Roche (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.